Investigational drug · Phase 3
JW0104
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Hypertension, Dyslipidemia.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 9, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "JW0104"
First trial start
2024
Dec 2, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JW0104", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hypertension
- Dyslipidemia
Approved drugs for the same conditions: High blood pressure (hypertension) · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "JW0104" as an intervention, largest first.
- Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and DyslipidemiaPivotal-lookingRecruiting
JW PharmaceuticalIndustry
NCT06643130 · 162 participants (planned) · Start Dec 2, 2024 · Primary completion Apr 2026
Drug: JW0104+C2402; JW0104+C2403 and 1 more · For: Hypertension; Dyslipidemia
Sites: Seoul, South Korea
JW PharmaceuticalIndustry
NCT06754943 · 60 participants · Start Jan 17, 2025 · Primary completion Mar 24, 2025
Drug: Treatment A_Period 1; Treatment B_Period 2 and 6 more · For: Healthy
Sites: Anyang-si, South Korea
JW PharmaceuticalIndustry
NCT06378684 · 48 participants · Start Sep 10, 2023 · Primary completion Dec 23, 2023
Drug: Group 1: JW0104(Period 1), C2207(Period 2), JW0104 + C2207(Period 3); Group 2: JW0104 + C2207(Period 1), JW0104(Period 2), C2207(Period 3) and 4 more · For: Healthy
Sites: Seoul, South Korea
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Hypertension
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- CagriSemaCagrilintide B and Semaglutide IPhase 36 trials
Novo Nordisk · Obesity, Diabetes Mellitus, Type 2, Hypertension
- lorundrostatPhase 35 trials
Mineralys Therapeutics Inc. · Hypertension, Obstructive Sleep Apnea, Chronic Kidney Disease
- VCT220CX11Phase 35 trials
Vincentage Pharma Co., Ltd · Obesity, Type 2 Diabetes Mellitus (DM), Hypertension
- VicadrostatBI 690517Phase 35 trials
Boehringer Ingelheim · Heart Failure, Diabetes Mellitus, Type 2, Hypertension
- ZilebesiranALN-AGT01Phase 34 trials
Alnylam Pharmaceuticals · Hypertension, High Cardiovascular Risk, High Risk Cardiovascular Disease
- ClazakizumabLY5724886, CSL300Phase 32 trials
Eli Lilly · Atherosclerosis, Cardiovascular Disease, Obesity
- DWC202314Phase 32 trials
Daewoong Pharmaceutical Co. LTD. · Essential Hypertension, Hypertension
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.